GSTM1 and chronic kidney disease: ,78 The practice of targeting lower Hb levels in CKD has been guided by the undesirable results of large-scale studies regarding the safety and efficacy of ESA therapy targeting high Hb target levels in patients with CKD.79, 80, 81